Peregrine Capital Management LLC Purchases 73,868 Shares of ADMA Biologics Inc $ADMA

Peregrine Capital Management LLC grew its position in ADMA Biologics Inc (NASDAQ:ADMA) by 16.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 530,524 shares of the biotechnology company’s stock after purchasing an additional 73,868 shares during the quarter. Peregrine Capital Management LLC owned approximately 0.22% of ADMA Biologics worth $7,777,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Financial Consulate Inc. purchased a new position in shares of ADMA Biologics during the 3rd quarter valued at $44,000. Salomon & Ludwin LLC bought a new stake in ADMA Biologics during the third quarter valued at about $25,000. Inspire Investing LLC lifted its position in shares of ADMA Biologics by 47.8% in the third quarter. Inspire Investing LLC now owns 31,314 shares of the biotechnology company’s stock valued at $459,000 after acquiring an additional 10,132 shares in the last quarter. Harbor Capital Advisors Inc. purchased a new position in shares of ADMA Biologics in the third quarter valued at about $877,000. Finally, Farther Finance Advisors LLC boosted its stake in shares of ADMA Biologics by 30.8% in the third quarter. Farther Finance Advisors LLC now owns 9,410 shares of the biotechnology company’s stock worth $138,000 after acquiring an additional 2,214 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA opened at $17.95 on Friday. The company has a market cap of $4.27 billion, a P/E ratio of 20.87 and a beta of 0.47. ADMA Biologics Inc has a 52-week low of $13.50 and a 52-week high of $25.67. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.65 and a current ratio of 7.13. The firm’s fifty day moving average is $18.04 and its two-hundred day moving average is $17.13.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.The firm had revenue of $134.22 million during the quarter, compared to analyst estimates of $131.20 million. During the same quarter last year, the business posted $0.15 earnings per share. The business’s quarterly revenue was up 12.0% compared to the same quarter last year. As a group, analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, ADMA Biologics currently has an average rating of “Buy” and an average target price of $28.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.